Researchers in St. Louis have launched a study into whether a long-used antidepressant can reduce the likelihood that COVID-19 will turn deadly.
Researchers at Washington University School of Medicine are recruiting COVID-19 patients for a clinical trial that will examine whether an existing anti-depressant can be an effective treatment for COVID-19.
Washington University in St. Louis will begin construction in March on what will be one of the largest neuroscience research buildings in the country.
Neuroactive steroid drugs result from Taylor Family Institute, pharma collaboration
Professorship supports research in new treatment strategies for psychiatric illness
Glowinski, artist Outlaw address mental health through artwork.
Adam Kepecs, PhD, recognized internationally for his research on neural circuits responsible for cognition and decision-making, has been named a BJC Investigator and a professor of neuroscience and psychiatry at Washington University School of Medicine in St. Louis.
Philanthropists Andrew and Barbara Taylor and the Crawford Taylor Foundation have committed $10 million to Washington University School of Medicine in St. Louis to continue research to investigate the scientific underpinnings of psychiatric illnesses, with the goal of improving diagnosis and treatment.
"The Taylor Family Institute for Innovative Psychiatric Research is pleased to announce the installment of Dr. Doug Covey as the inaugural Taylor Family Distinguished Professor of Psychiatry. Doug's medicinal chemistry work resulted in his co-founding of Sage Therapeutics, which recently brought brexanolone to market as the first drug to treat post-partum depression."
Adult depression has long been associated with shrinkage of the hippocampus, a brain region that plays an important role in memory and response to stress. Now, new research from Washington University in St. Louis has linked participation in team sports to larger hippocampal volumes in children and less depression in boys ages 9 to 11.
A biomedical engineer at Washington University in St. Louis is developing a therapeutic option that would prevent the opiates from crossing the blood-brain barrier, preventing the high abusers seek.
Blocking a type of opioid receptor restores motivation